A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

March 5, 2017

Primary Completion Date

December 13, 2019

Study Completion Date

December 13, 2019

Conditions
Diabetes Mellitus, Type 2Non-Alcoholic Fatty Liver Disease
Interventions
DRUG

BFKB8488A

Administered subcutaneously starting on Day 1 and according to dosing schedule.

OTHER

Placebo

Administered subcutaneously starting on Day 1 and according to dosing schedule.

Trial Locations (18)

28150

Carolina Research Center at Jones Family Practice, Shelby

30328

Agile Clinical Research Trials, Atlanta

33009

MD Clinical, Hallandale

33165

Premier Research Associate, Inc, Miami

36207

Pinnacle Research Group Cullman, Anniston

Pinnacle Research Group; Llc, Central, Anniston

37920

New Orleans Center for Clinical Research, Knoxville

66209

MidWest Clinical Research, Overland Park

75230

Dallas Diabetes & Endocrine Center, Dallas

76012

Texas Clinical Research Institute, LLC, Arlington

78229

Clinical Trials of Texas Incorporated, San Antonio

78231

Consano Clinical Research, Shavano Park

78249

Northeast Clinical Research of San Antonio LLC, San Antonio

92118

Southern California Research Center, Inc., Coronado

92780

Diabetes Research Center, Tustin

94305

Stanford Health Care, Stanford

08009

Hassman Research Institute, Berlin

H3X 2H9

inVentiv Health Clinical, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY